Food and Drug Administration has given green signal for the first HIV drug, which will prove to be beneficiary in combating the disease.

The drug initially sold under the name of Truvada, was prescribed for almost 10 years to those carrying the infection. The drug is now to be sold as pre-exposure prophylaxis, meaning it is specially designed for high-risk individuals who test negative for HIV when they start using the drug.

However, drug representatives from local agencies, who assist people infected with HIV/AidS, have raised concerns over the security of the drug use. They have emphasized that the cost of the drug might not be affordable for all those, who can make benefit out of it.

Lisa Terry, executive director of the AIDS Task Force of Northeast Indiana, said “I don't want folks to think that this is a pop-a-pill prevention. If people are hearing about Truvada, I don't have to use condoms”.

Truvada is not a new drug as it has been prescribed for more than ten years now to people who have been diagnosed with HIV. Experts say that there are many concerns which need to be dealt with the drug. One of the concerns is price of the drug, which makes it difficult for majority of HIV sufferers to take benefit out of it.